Member Info for Moneymunch

WHO WE ARE

Pioneering Novel Gene Therapeutics for a Longer, Healthier Life

MISSION: aging is underlying risk factor for disease, and our aim is to deliver

gene therapeutics that potentially halt or slow the aging process in humans and dogs

CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases

PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH

SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs

DEVELOPMENT PIPELINE

GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver

GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts

GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6

GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma

OPHTHALMOLOGY PLATFORM

New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow’s proprietary Centenarian SIRT6 (cent SIRT6).

Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye.

Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system.

LEVERAGING AI FOR GENOMICS

New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles.

Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes.

Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH.

GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON

The Problem

80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC

death is irreversible; unmet need for neuroprotection Significant market opportunity

The Gap

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

2,222 followers

2h

Took a look at Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s latest presentation!

Learn about #GENF's exciting path forward with Centenarian #SIRT6 studies, impressive financials, and its mission to redefine the #aging process.

Find it here: hTtps://loom.ly/RsxnFCE

#GENF #GENFF #Biotech #MASH #WernerSyndrome #Sarcopenia

Very exciting indeed Porter, planned meetings presumably with potential suitors at JP Morgan next week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, and so every chance for little old Genflow. Excitement building and everything firmly crossed. :-)

Ps jamtart, as far as value goes, Genflow's current market cap is a lowly £9.5m and so if they announced a deal for £100m, then a market cap of £100m wouldn't be out of the question and so a 10 bagger in a blink, and who knows, maybe 20, 50 or even a 100 bagger depending on the size and number of any deals secured....the sky is the limit!!! Gl :-)

Something similar for Genflow's Sirt6 Gene Therapy for Glaucoma with their leading Ophthalmology company more than conceivable. A Material Transfer Agreement was signed in April 2025 and so positive data, along with Efficacy Data from the Dog Trial in liaison with the two Animal Healthcare companies who have both signed Confidential Disclosure Agreements, could be presented at next weeks JP Healthcare Conference. Gla holders, a very exciting period ahead!!! :-)

6/1/26

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a doctor’s office.

Ikarovec’s IKAR-003 is currently in preclinical development for intermediate age-related macular degeneration (AMD). The one-time injectable therapy is designed to prevent the progression of this eye disease by offering both neuroprotection and complement modulation.

The fledgling partnership is still at an early stage. For now, the technology will be evaluated before the companies fully commit. But, assuming the deal is finalized, it is expected to be worth more than $1 billion.

UK biotech eyes $1B deal to deliver eye gene therapy at doctor hTtps://share.google/t12NrOU65ISH49HrO

All bodes well and another compelling recent research paper on Sirt6's panacea potential. Genflow's cutting edge science and Sirt6 technology platform could be of huge interest to Major Pharma. Gla :-)

Sirt6 Deficiency Spurs Obesity Inflammation via Galectin-3

Bioengineer by Bioengineer

January 6, 2026

In a transformative breakthrough that may reshape our understanding of obesity-related inflammation, researchers have uncovered a pivotal molecular mechanism involving Sirt6 deficiency in mast cells that exacerbates adipose tissue fibroinflammation. This discovery, detailed in a recent publication in Nature Communications, illuminates the complex interplay between immune cells and fat tissue, identifying galectin-3 signaling as the critical conduit driving inflammatory and fibrotic processes within the adipose microenvironment during obesity.

.......

These findings have far-reaching implications, extending beyond fundamental science into translational and clinical paradigms. By establishing mast-cell Sirt6 as a critical regulator of adipose tissue homeostasis, the study opens new avenues for innovative obesity treatments aimed at curbing fibroinflammatory processes. Pharmacological enhancement of Sirt6 activity or galectin-3 blockade may emerge as promising strategies to restore adipose tissue integrity and improve metabolic outcomes.

......

In conclusion, the identification of Sirt6 deficiency in mast cells as a driver of adipose tissue inflammation and fibrosis via galectin-3 signaling marks a paradigm shift in obesity research. This innovative study positions mast cell epigenetic regulation at the heart of metabolic inflammation, providing a novel therapeutic target that could change the landscape of obesity treatment and improve outcomes for millions worldwide.

Sirt6 Deficiency Spurs Obesity Inflammation via Galectin-3 https://share.google/m8sEZOt5Vl59Dq7Pc

At the 44th J.P. Morgan Healthcare Conference (JPM 2026) in San Francisco (Jan 12-15, 2026), longevity is a significant theme, with companies like Genflow Biosciences pitching gene therapies and AI-driven health solutions, alongside broader discussions on breakthrough therapies, digital health, and investment trends shaping the aging and wellness sectors. Expect many partnering meetings, innovation showcases, and discussions on AI's role in transforming care for aging populations.

Key Longevity & Related Themes at JPM 2026:

Gene Therapies: Companies like Genflow Biosciences are presenting novel approaches, such as SIRT6 gene delivery, for age-related conditions and overall longevity.

AI & Digital Health: Central to discussions are how AI-powered tools (predictive analytics, diagnostics) and digital platforms are revolutionizing wellness, patient engagement, and care for aging individuals.

Investment Focus: Investors are looking at innovative health solutions, including those addressing chronic diseases, metabolic health (like MASH), and age-related conditions.

Breakthrough Therapies: Focus areas include oncology, neurology, hematology, and broader advancements in immunology and precision medicine relevant to longevity.

Investor Partnering: Concurrent events like RESI JPM facilitate connections between investors and early-stage companies developing next-gen health technologies.

Why It Matters:

JPM is the premier healthcare investment event, setting the tone for the year; the strong presence of longevity-focused innovation signals major investor interest in extending healthy lifespans.

All bodes well Porter, continued share accumulation in anticipation of a stellar year ahead.....potential exponential UPside fast approaching!!! Gl :-)

Dr. Eric Leire, CEO of Genflow, commented: "We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space."

As the industry looks ahead to 2026, the upcoming JP Morgan Healthcare conference will be a pivotal indicator on the direction for the biopharma sector for 2026. The event will set the tone for dealmaking, capital flow and R&D priorities in the year ahead, as executives look to reaffirm investor confidence, aligning on the next wave of scientific and commercial breakthroughs to strengthen pipelines.

Hans concludes: “As we look to 2026, strong drug pipelines and breakthrough clinical catalysts will drive the sector, as pricing pressures are addressed, innovation and differentiation will take centre stage, and strategic deals accelerate growth and portfolio transformation.”

Biopharma enters 2026 with renewed and cautious optimism - PharmaLive hTtps://share.google/ocZAE3qqVWqcU9iyA

Or maybe this time next month!!!??? Gla holders and a very Happy and Prosperous New Year!!! :-)

Latest compelling research into Sirt6's panacea potential.....what Major Pharma wouldn't be interested in Genflow's Sirt6 technology platform? Gla holders:-)

22/12/25

Brain enzyme discovery may open new path to treat neurodegenerative disease

Using human cell lines alongside mouse and fruit fly models, Toiber's team identified the enzyme sirtuin 6, or SIRT6, as the central regulator. SIRT6 is known for its role in longevity, but the study shows it also functions as a gatekeeper of tryptophan metabolism.

......

"Our research positions the enzyme SIRT6 as a critical and primary drug target to combat degenerative brain pathology," Toiber said. "These findings change the way we understand the relationship between aging and brain function. It is not simply wear and tear, but a specific metabolic malfunction that can be corrected."

SIRT6 Enzyme: Breakthrough Discovery in Brain Enzyme Offers Hope for Treating Neurodegenerative Diseases, ETHealthworld https://share.google/zJ2xD65yVvrV7kAJG

The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK.

Key Regulatory Changes and Their Impact on Small Cap Fundraising

The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies:

Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.

23 Jul '25

View organization page for Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

2,002 followers

3h

📣 New regulatory developments in the UK are expected to facilitate future financing flexibility. Under new Financial Conduct Authority (FCA) rules, effective 19 January 2026 and published in a policy statement on 15 July 2025, smaller R&D intensive companies such as Genflow Biosciences (LON:GENF) (OTCQB:GENFF) will be able to raise capital for its programs on the London Stock Market without restrictions on the size of equity issuances.

These changes, part of broader UK capital markets reform, are designed to simplify the prospectus regime, lower costs, and improve access to retail investors.

🔗 hTtps://lnkd.in/eqtB8dc2

The Financial Conduct Authority (FCA) has introduced significant changes to the UK's public offers and admissions to trading regime, effective 19 January 2026, which will substantially ease the fundraising process for small-cap and growth companies. These reforms aim to reduce costs, streamline processes, and boost the competitiveness of the UK's capital markets.

Key changes for small-cap fundraising include:

Increased Prospectus Threshold For companies already admitted to trading on a regulated market, the threshold for requiring a full prospectus when issuing new shares has been increased significantly from 20% to 75% of existing share capital. This allows listed small-cap firms to conduct larger, faster secondary fundraisings (such as placings or rights issues) with less regulatory burden.

Cash is King Northeast, and disappointing we're still awaiting the non-dilutive funding, although no doubt out of Eric's hands. The Belgium/ Wallonia Govt are dealing with one of the largest budget deficits in Europe and have been in turmoil most of this year as the coalition Govt were at odds on how to deliver the new budget and savings for this coming year, which obviously includes painful cut backs across all services as they try and plan to reduce the deficit over the next few years. Whether or not this includes cut backs in non-dilutive grant funding remains to be seen as Wallonia/Biowin are still advertising for new applications for 2026, and so still a chance it could arrive. The £440k fund raise in October provides enough cash for Genflow’s near term commitments, specifically the Dog Trial and efficacy readout, and Eric's participation along with the consortium of long term Major Shareholders, speaks volumes in their confidence going forward, and we're now fast approaching an incredibly exciting time with Genflow's invitation to the JP Morgan HealthCare Conference with planned meetings with potential suitors, no doubt and hopefully armed with positive efficacy data from the Dog Trial, which will have huge implications across the pipeline and Sirt6 platform, whereby the chances of a Major deal announcement with an Animal Health Company, or a leading Ophthalmology Company or indeed a Major Pharma for the whole platform , couldn't look better and would be transformational for all invested. Everything firmly crossed!!! Gl:-)

Ps from 19th January 2026, new FCA regulations are going to significantly reduce the costs for small caps to raise funds, which will revolutionise the prospects and potential for small caps going forward. So all bases covered. Gl :-)

Genflow Biosciences CEO discusses next steps as canine gene therapy trial hits milestone

Published: 11:00 16 Dec 2025

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s progress in its canine gene therapy trial targeting sarcopenia.

Leire confirmed that the dosing phase has now been completed with no adverse effects, calling it a key milestone in de-risking the SIRT6 programme for potential pharma partners and investors. He said, “We demonstrated some kind of safety, with the full dosing, we had to observe no side effect, no adverse side effect, even minor event.”

Leire explained the study’s scientific rigour, highlighting its randomised, controlled and blinded design using aged dogs not previously involved in clinical trials. This, he said, addresses a major unmet need in the life extension field, with industry experts previously considering such a study “impossible to do.”

Looking ahead, efficacy data is expected in January, with analysis focused on multiple endpoints. These include mitochondrial function, clinical data, muscle biopsies, and epigenetic markers like the methylation clock in collaboration with UCLA. Leire said the results could influence other Genflow programmes, including preclinical work on NASH, Werner syndrome and ophthalmology.

He noted that Genflow is in licensing discussions with several animal health companies and reiterated that while Genflow is not an animal health business, a potential deal could be shaped by the strength of the efficacy data.

Great news and great timing , and maybe first efficacy readout in time for the prestigious JP Healthcare Conference. Exciting times!!! Gl :-)

Completion of Dosing Phase of Canine Gene Therapy

GENFLOW BIOSCIENCES PLC

Released 07:00:08 16 December 2025

RNS Number : 7366L

Genflow Biosciences PLC

16 December 2025

Genflow Biosciences Plc

Genflow Completes Dosing Phase of Canine Gene Therapy Trial

No Adverse Events Reported During Administration

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on extending healthspan through advanced gene therapies, today announced that all dogs enrolled in its ongoing clinical trial have successfully received the full administration of the Company's investigational SIRT6-based gene therapy.

Importantly, no adverse events were reported during the dosing phase of the study. No serious, moderate, or minor side effects were observed, demonstrating a strong safety and tolerability profile for the therapy.

The study is being conducted as a blinded clinical trial and, as such, efficacy outcomes cannot yet be assessed. Genflow expects a first efficacy read in mid-to-late January 2026, which will include blood analyses and muscle biopsies to evaluate potential therapeutic benefits related to sarcopenia, overall healthspan, and lifespan-associated biomarkers.

The dogs enrolled in the trial will continue to be monitored for a total duration of 180 days. A second efficacy assessment is planned at the six-month timepoint, with results expected in June-July 2026, to evaluate durability and longer-term effects of the gene therapy.

Following analysis of the efficacy data, Genflow intends to resume discussions with several animal health companies, including parties currently engaged under confidentiality and data access agreements, to explore potential early-stage licensing opportunities.

Dr. Eric Leire, CEO of Genflow, commented: "These milestones represent an important step forward for our longevity program. The absence of any adverse events is highly encouraging and reinforces the strong safety profile of our approach. We look forward to sharing initial efficacy data in the coming months as the study progresses."

Mark Your Calendars: 2028 Could Be the Year

If all goes according to plan, human trials will begin in about 18 months, with the drug potentially hitting the Israeli market within three years.

“This drug isn’t about immortality,” explains Dr. Hagit Ashush, VP of R&D at Sirtlab. “It’s about delaying the onset of age-related diseases and improving quality of life in later years. Our goal is to slow aging itself.”

Healthy competition for Genflow, but certainly highlights the incredible potential and prospects of Genflow's Sirt6 Gene Therapy R & D, which could be slightly ahead of the curve, given the safety profile of Genflow's Sirt6 has been established and confirmed twice with no ill effects in the current Dog Trial, and with human trials for Mash expected/planned for this coming year. The Chief Medical Advisor at Sirtlab, Dr. Nir Barzilai, is also a Director/Professor at Albert Einstein College of Medicine in New York who along with the University of Rochester and Columbia University, jointly own the Sirt6 patent "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases" and Genflow holds the exclusive worldwide license to this intellectual property.

All bodes well and all very exciting as Genflow prepares to impress and wow at the upcoming JP Morgan HealthCare Conference. Gla holders;-)

April 2025

The Pill That Could Change Everything

Living longer and feeling younger. That’s the promise behind Sirtlab, the innovative Israeli startup that is on the verge of redefining aging—and extending human life by up to 30%

The Pill That Could Change Everything

“SIRT-6 doesn’t just help us live longer—it helps us live better,” says Prof. Haim Cohen, founder and chief scientist at Sirtlab and head of the Sagol Center for Healthy Aging at Bar-Ilan University. “We’ve managed to elevate SIRT-6 levels in older test subjects to those typically seen in much younger individuals, and the effects are stunning.”

According to Cohen, the increased activity of SIRT-6 has been linked to improved memory, better liver function, and even hair regrowth. “In our studies, older animals with enhanced SIRT-6 activity performed as well as their younger counterparts, physically and cognitively.”

A New Era in Aging

The treatment is currently one step away from human trials. So far, results in animals have been promising: older subjects not only lived longer but showed energy levels, physical performance, and bodily functions similar to the young.

“We’re hopeful this translates to humans,” says Prof. Eitan Friedman, director of Oncogenetics at Assuta Medical Center. “If the upcoming clinical trials confirm these results, this could be a true game-changer. I’m cautiously optimistic.”

Big Backing for Big Science

*Sirtlab* has already raised millions of dollars and plans to raise more via the investment platform PeopleBiz, accelerating the development process. CEO Boaz Mashuoli emphasizes the global importance of the research: “We believe this treatment could significantly contribute to the future of human health. But first, we need to complete additional safety testing in animals before moving on to clinical trials.”

Mark Your Calendars: 2028 Could Be the Year

If all goes according to plan, human trials will begin in about 18 months, with the drug potentially hitting the Israeli market within thr